Business
Regeneron Pharmaceuticals Inc. said it has been awarded a patent covering the gene for a biotechnology-based protein that Regeneron and Amgen Inc. are developing to treat neurological diseases.
Jan. 26, 1993
World & Nation
U.S. health officials have allowed emergency use of a Regeneron antibody drug to help the immune system fight COVID-19.
Nov. 21, 2020
Amgen Inc., a Thousand Oaks biotechnology concern, said it entered into a multiyear pact with Regeneron Pharmaceuticals Inc. to develop certain proteins, called neurotropic factors, that might be developed into biotechnology drugs that could help treat various neurological disorders.
Sept. 11, 1990
Regeneron Pharmaceuticals Inc., a fledgling biotechnology company that’s partially owned by Amgen Inc. in Thousand Oaks, has taken a few more baby steps on its long journey toward producing marketable drugs.
Feb. 11, 1992
Regeneron Pharmaceuticals Inc., which caused a splash on Wall Street when it went public recently, hopes one day to be the next Amgen Inc.
April 16, 1991
May 1, 1991
Amgen Inc., the Thousand Oaks biotechnology firm, says encouraging test results have been obtained for a drug it is co-developing with a New York firm to treat amyotrophic lateral sclerosis, or Lou Gehrig’s disease.
July 11, 1995
Biotechnology: Both firms are disappointed their drug to combat Lou Gehrig’s disease is a failure.
Jan. 11, 1997
Biogen Idec Inc.’
April 21, 2005
Amgen Inc., the Thousand Oaks biotechnology giant, has signed a joint-research agreement with Medtronic Inc. of Minneapolis in an effort to treat such nerve disorders as Lou Gehrig’s disease.
May 24, 1994